Database for patients treated with metabolic radiotherapy
Establishment of a Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
NA · Institut du Cancer de Montpellier - Val d'Aurelle · NCT04104529
This study is creating a database to collect information and samples from patients with thyroid, prostate, and neuroendocrine tumors who are receiving targeted radiation therapy, to see how it works and improve treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle (other) |
| Drugs / interventions | radiation |
| Locations | 4 sites (Bordeaux, Aquitaine and 3 other locations) |
| Trial ID | NCT04104529 on ClinicalTrials.gov |
What this trial studies
This project aims to develop a clinico-biological database that collects clinical data and biological materials from patients undergoing targeted radionuclide therapy (TRT) for thyroid cancer, prostate cancer, and neuroendocrine tumors. The study will utilize various radionuclides to deliver radiation specifically to tumor cells, enhancing treatment effectiveness. By integrating clinical and biological data, the research seeks to improve understanding of the radiobiological effects of TRT and optimize treatment strategies. The database will also facilitate collaboration among researchers to advance medical knowledge and patient care.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are being treated with metabolic radiotherapy for thyroid cancer, prostate cancer, or neuroendocrine tumors.
Not a fit: Patients who are not affiliated with a social security scheme or those in emergency situations may not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could lead to improved treatment outcomes for patients with thyroid cancer, prostate cancer, and neuroendocrine tumors.
How similar studies have performed: Other studies utilizing targeted radionuclide therapy have shown promising results, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ at 18 years old, * Patient treated in the Nuclear Medicine Department for the treatment by metabolic radiotherapy, * Patient treated as part of his treatment for: * thyroid cancer, * a neuroendocrine tumor or * prostate cancer. * Patient having accepted the complementary blood sample, * Patient having given his informed, written and express consent. Exclusion Criteria: * Patient not affiliated to a social security scheme, * Subject under tutelage, curatorship or safeguard of justice, * Patient in an emergency situation * Patient whose regular monitoring is a priori impossible for psychological, family, social or geographical reasons, * Pregnant and / or breastfeeding woman
Where this trial is running
Bordeaux, Aquitaine and 3 other locations
- Hopital Haut Lévêque — Bordeaux, Aquitaine, France (RECRUITING)
- Hôpital LaTimone — Marseille, Bouches Du Rhône, France (NOT_YET_RECRUITING)
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle — Montpellier, France (RECRUITING)
- Institut Universitaire du Cancer de Toulouse — Toulouse, France (RECRUITING)
Study contacts
- Study coordinator: Aurore MOUSSION
- Email: DRCI-icm105@icm.unicancer.fr
- Phone: 0467613102
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Thyroid Cancer, Prostate Cancer, Neuroendocrine Tumors, thyroid cancer, prostate cancer, neuroendocrine tumors, nuclear medecine